By: Skylar Jeremias From: centerforbiosimilars.com Authors of a systematic review summarized the results of 21 published studies on the efficacy, safety, and cost-benefit ratio of trastuzumab biosimilars in human epidermal growth factor receptor 2 (HER2)-positive breast cancer. The HER2 Receptor and Trastuzumab Use in HER2-positive Breast Cancer HER2 is a cell surface receptor activated by epidermal growth factor that upon …
Neoadjuvant and Adjuvant Therapy Elicit Similar Efficacy in Early-Stage HER2+ Breast Cancer
By: Chris Ryan From: onclive.com Neoadjuvant therapy generated similar benefits to adjuvant therapy in patients with early-stage, HER2-positive breast cancer treated in China, suggesting that neoadjuvant therapy should be used in this patient population, according to data from a real-world retrospective study published in The Breast.1 At a median follow-up of 54.1 months (interquartile range, 40.8-68.9), all patients treated with …
FDA expands Enhertu approval for breast cancer
From: healio.com The FDA expanded the approval of fam-trastuzumab deruxtecan to include treatment of patients with HER2-positive metastatic breast cancer who received a prior anti-HER2-based regimen. Fam-trastuzumab deruxtecan (Enhertu; AstraZeneca, Daiichi Sankyo) is a novel antibody-drug conjugate with three components: a humanized anti-HER2 immunoglobulin G1 monoclonal antibody with the same amino acid sequence as trastuzumab (Herceptin, Genentech); a topoisomerase 1 …
Puma Biotechnology’s NERLYNX® Included in Two Important NCCN Clinical Practice Guideline Updates for the Treatment of Breast Cancer
From: businesswire.com Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) for the treatment of breast cancer have been updated for 2022 and include two important changes involving neratinib (NERLYNX®). The first update added NERLYNX to the body of the guidelines for the treatment of adjuvant …
Clinical trial demonstrates focused ultrasound can deliver antibody therapy to breast cancer metastases in the brain
By: Focused Ultrasound Foundation From: medicalxpress.com In a first-in-world clinical trial, researchers at Sunnybrook Health Sciences Centre in Toronto, Canada, have demonstrated that magnetic resonance (MR)-guided focused ultrasound can be used to safely deliver antibody therapy to breast cancer that has metastasized to the brain. In this Phase I clinical trial for Her2-positive breast cancer patients, the Sunnybrook team captured …
Could Your Patient Benefit? New Clinical Trials in Breast Cancer
By: Helen Leask From: medscape.com A number of phase 3 studies in breast cancer have opened in recent months. Maybe one of your patients could benefit from being enrolled? Advanced HER2+ breast cancer. Patients with previously treated advanced or metastatic HER2+ breast cancer with and without brain metastases are sought for the DESTINY-B12 trial of trastuzumab deruxtecan (Enhertu). Patients will …
New Drug Combo Boosts Survival Against Aggressive Form of Breast Cancer
By: Denise Mann, HealthDay Reporter From: webmd.com New research offers good news for women with an aggressive HER2-positive breast cancer. A targeted therapy, trastuzumab deruxtecan (T-DXd), sold as Enhertu, triples the length of time that the cancer remains in check when compared with the current gold standard, trastuzumab emtansine (T-DM1). Both of these drugs are second-line treatment options for HER2-positive …
Third-Line Treatment Data for HER2+ Advanced Breast Cancer
By: Sara Hurvitz, MD, Steven Vogl, MD From: cancernetwork.com Sara Hurvitz, MD: Welcome to CancerNetwork® Between the Lines. We are going to be reviewing a Journal Club experience titled “Third-Line Treatment of HER2-Positive Advanced Breast Cancer: From No Standard to a Pandora’s Box.” My name is Dr Sara Hurvitz. I’m a breast cancer medical oncologist practicing at the University of …
Enhertu improves survival in Phase III breast cancer trial
From: europeanpharmaceuticalreview.com Enhertu (trastuzumab deruxtecan) significantly improved survival in the DESTINY-Breast03 Phase III head-to-head trial against trastuzumab emtansine. Positive high-level results from the head-to-head DESTINY-Breast03 Phase III trial has shown that Enhertu (trastuzumab deruxtecan) demonstrates superiority over trastuzumab emtansine (T-DM1) in treating HER2-positive metastatic breast cancer. Enhertu is an HER2-directed antibody drug conjugate (ADC) developed by AstraZeneca and Daiichi Sankyo, …
KAMILLA Data Reinforce Favorable Benefit/Risk Profile of T-DM1 in HER2+ Breast Cancer
By: Ryan Scott From: onclive.com Rachel Wuerstlein, MD, discusses the safety and the efficacy observed with ado-trastuzumab emtansine in patients with HER2-positive breast cancer and the next steps for research with the agent. Data from the phase 3 KAMILLA trial (NCT01702571) confirm the safety and efficacy of ado-trastuzumab emtansine (T-DM1, Kadcyla) that had previously been observed in patients with previously …